Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib for BOS After Allogeneic HCT
NCT04239989Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in Bronchiolitis Obliterans Syndrome (BOS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose Limiting Toxicities at 6 months. Started Oct 2021; status: terminated.
02
Drugs
itacitinib
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT04239989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239989.